Form 20-F ☑
|
Form 40-F ☐
|
Yes ☐
|
No ☑
|
EXFO INC.
|
|
By: /s/ Philippe Morin
Name: Philippe Morin
Title: Chief Executive Officer
|
|
§
|
Sales total US$63.4 million, above midpoint of guidance range
|
§
|
Bookings attain US$65.9 million, book-to-bill ratio of 1.04
|
§
|
Gross margin improves to 63.3% of sales
|
§
|
Adjusted EBITDA reaches US$6.1 million, 9.6% of sales
|
Q1 2018
|
Q4 2017
|
Q1 2017
|
||||||||||
Physical-layer sales
|
$
|
42,513
|
$
|
40,802
|
$
|
42,016
|
||||||
Protocol-layer sales
|
20,641
|
22,122
|
20,009
|
|||||||||
Foreign exchange gains (losses) on forward exchange contracts
|
237
|
57
|
(240
|
)
|
||||||||
Total sales
|
$
|
63,391
|
$
|
62,981
|
$
|
61,785
|
||||||
Physical-layer bookings
|
$
|
48,352
|
$
|
39,322
|
$
|
44,090
|
||||||
Protocol-layer bookings
|
17,290
|
26,943
|
22,009
|
|||||||||
Foreign exchange gains (losses) on forward exchange contracts
|
237
|
57
|
(240
|
)
|
||||||||
Total bookings
|
$
|
65,879
|
$
|
66,322
|
$
|
65,859
|
||||||
Book-to-bill ratio (bookings/sales)
|
1.04
|
1.05
|
1.07
|
|||||||||
Gross margin before depreciation and amortization*
|
$
|
40,102
|
$
|
39,009
|
$
|
38,972
|
||||||
63.3
|
%
|
61.9
|
%
|
63.1
|
%
|
|||||||
Other selected information:
|
||||||||||||
IFRS net earnings
|
$
|
2,679
|
$
|
844
|
$
|
3,303
|
||||||
Amortization of intangible assets
|
$
|
1,119
|
$
|
1,048
|
$
|
427
|
||||||
Stock-based compensation costs
|
$
|
402
|
$
|
431
|
$
|
258
|
||||||
Restructuring charges
|
$
|
‒
|
$
|
1,266
|
$
|
‒
|
||||||
Changes in fair value of cash contingent consideration
|
$
|
(155
|
)
|
$
|
(383
|
)
|
$
|
‒
|
||||
Net income tax effect of the above items
|
$
|
(172
|
)
|
$
|
(275
|
)
|
$
|
(64
|
)
|
|||
Foreign exchange (gain) loss
|
$
|
(1,218
|
)
|
$
|
2,943
|
$
|
(512
|
)
|
||||
Adjusted EBITDA*
|
$
|
6,059
|
$
|
8,545
|
$
|
6,321
|
·
|
Sales. Sales increased 2.6% year-over-year mainly due to the ongoing 100G optical investment cycle as well as the positive impact of the recent Yenista Optics and Ontology Systems acquisitions. Physical-layer sales accounted for 67% of total revenue in the first quarter of 2018, while Protocol-layer sales totaled 33%. Revenue distribution among the three main selling regions in the first quarter amounted to 53% in the Americas, 23% in Europe, Middle East and Africa (EMEA) and 24% in Asia-Pacific. EXFO's top customer accounted for 13.8% of sales, while the top three represented 21.6%.
|
·
|
Profitability. EXFO generated adjusted EBITDA of US$6.1 million, or 9.6% of sales, in the first quarter of 2018 compared to US$6.3 million, or 10.2% of sales, in the first quarter of 2017. The company also delivered US$2.4 million in cash flows from operating activities in the first quarter of 2018.
|
·
|
Innovation. EXFO launched four new products or major enhancements in the first quarter of fiscal 2018 including EX1, a multipurpose test solution for validating bandwidth speed up to full line rate Gigabit Ethernet and for monitoring quality of experience at customer premises; a compact 400G test solution for network equipment manufacturers, carrier labs and data centers; an optical spectrum analyzer delivering in-service optical signal-to-noise ratio (OSNR) measurements for networks up to 400G; and a power meter that automatically detects and adapts test parameters for passive optical network (PON) technology in use at customer premises.
|
Q1 2018
|
Q4 2017
|
Q1 2017
|
||||||||||
IFRS net earnings for the period
|
$
|
2,679
|
$
|
884
|
$
|
3,303
|
||||||
Add (deduct):
|
||||||||||||
Depreciation
|
1,154
|
1,008
|
903
|
|||||||||
Amortization
|
1,119
|
1,048
|
427
|
|||||||||
Interest and other (income) expense
|
338
|
275
|
(20
|
)
|
||||||||
Income taxes
|
1,740
|
1,113
|
1,962
|
|||||||||
Stock-based compensation costs
|
402
|
431
|
258
|
|||||||||
Restructuring charges
|
‒
|
1,266
|
‒
|
|||||||||
Change in fair value of cash contingent consideration
|
(155
|
)
|
(383
|
)
|
‒
|
|||||||
Foreign exchange (gain) loss
|
(1,218
|
)
|
2,943
|
(512
|
)
|
|||||||
Adjusted EBITDA for the period
|
$
|
6,059
|
$
|
8,545
|
$
|
6,321
|
||||||
Adjusted EBITDA in percentage of sales
|
9.6
|
%
|
13.6
|
%
|
10.2
|
%
|
As at
November 30,
2017
|
As at
August 31,
2017
|
|||||||
Assets
|
||||||||
Current assets
|
||||||||
Cash
|
$
|
18,451
|
$
|
38,435
|
||||
Short-term investments
|
1,004
|
775
|
||||||
Accounts receivable
|
||||||||
Trade
|
39,784
|
41,130
|
||||||
Other
|
4,082
|
3,907
|
||||||
Income taxes and tax credits recoverable
|
4,664
|
4,955
|
||||||
Inventories
|
37,164
|
33,832
|
||||||
Prepaid expenses
|
3,946
|
4,202
|
||||||
109,095
|
127,236
|
|||||||
Tax credits recoverable
|
38,245
|
38,111
|
||||||
Property, plant and equipment
|
41,253
|
40,132
|
||||||
Investment in an associate (note 3)
|
9,706
|
‒
|
||||||
Intangible assets (note 3)
|
14,403
|
11,183
|
||||||
Goodwill (note 3)
|
39,204
|
35,077
|
||||||
Deferred income tax assets
|
6,599
|
6,555
|
||||||
Other assets
|
573
|
947
|
||||||
$
|
259,078
|
$
|
259,241
|
|||||
Liabilities
|
||||||||
Current liabilities
|
||||||||
Accounts payable and accrued liabilities
|
$
|
38,444
|
$
|
36,776
|
||||
Provisions
|
1,445
|
3,889
|
||||||
Income taxes payable
|
748
|
663
|
||||||
Deferred revenue
|
10,590
|
11,554
|
||||||
Current portion of long-term debt (note 7)
|
510
|
‒
|
||||||
51,737
|
52,882
|
|||||||
Deferred revenue
|
5,978
|
6,257
|
||||||
Long-term debt (notes 3 and 7)
|
1,595
|
‒
|
||||||
Deferred income tax liabilities
|
4,317
|
3,116
|
||||||
Other liabilities
|
374
|
196
|
||||||
64,001
|
62,451
|
|||||||
Shareholders' equity
|
||||||||
Share capital (note 8)
|
91,009
|
90,411
|
||||||
Contributed surplus
|
18,016
|
18,184
|
||||||
Retained earnings
|
129,839
|
127,160
|
||||||
Accumulated other comprehensive loss
|
(43,787
|
)
|
(38,965
|
)
|
||||
195,077
|
196,790
|
|||||||
$
|
259,078
|
$
|
259,241
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Sales
|
$
|
63,391
|
$
|
61,785
|
||||
Cost of sales (1) (note 9)
|
23,289
|
22,813
|
||||||
Selling and administrative (note 9)
|
23,193
|
21,595
|
||||||
Net research and development (note 9)
|
11,252
|
11,314
|
||||||
Depreciation of property, plant and equipment (note 9)
|
1,154
|
903
|
||||||
Amortization of intangible assets (note 9)
|
1,119
|
427
|
||||||
Change in fair value of cash contingent consideration (note 5)
|
(155
|
)
|
‒
|
|||||
Interest and other (income) expense
|
338
|
(20
|
)
|
|||||
Foreign exchange gain
|
(1,218
|
)
|
(512
|
)
|
||||
Earnings before income taxes
|
4,419
|
5,265
|
||||||
Income taxes (note 10)
|
1,740
|
1,962
|
||||||
Net earnings for the period
|
$
|
2,679
|
$
|
3,303
|
||||
Basic and diluted net earnings per share
|
$
|
0.05
|
$
|
0.06
|
||||
Basic weighted average number of shares outstanding (000's)
|
54,805
|
53,884
|
||||||
Diluted weighted average number of shares outstanding (000's) (note 11)
|
55,793
|
55,001
|
(1)
|
The cost of sales is exclusive of depreciation and amortization, shown separately.
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Net earnings for the period
|
$
|
2,679
|
$
|
3,303
|
||||
Other comprehensive income (loss), net of income taxes
|
||||||||
Items that will not be reclassified subsequently to net earnings
|
||||||||
Foreign currency translation adjustment
|
(4,130
|
)
|
(4,217
|
)
|
||||
Items that may be reclassified subsequently to net earnings
|
||||||||
Unrealized gains/losses on forward exchange contracts
|
(524
|
)
|
(561
|
)
|
||||
Reclassification of realized gains/losses on forward exchange contracts in net earnings
|
(383
|
)
|
181
|
|||||
Deferred income tax effect of gains/losses on forward exchange contracts
|
215
|
92
|
||||||
Other comprehensive loss
|
(4,822
|
)
|
(4,505
|
)
|
||||
Comprehensive loss for the period
|
$
|
(2,143
|
)
|
$
|
(1,202
|
)
|
Three months ended November 30, 2016
|
||||||||||||||||||||
Share
capital
|
Contributed surplus
|
Retained earnings
|
Accumulated other comprehensive loss
|
Total
shareholders' equity
|
||||||||||||||||
Balance as at September 1, 2016
|
$
|
85,516
|
$
|
18,150
|
$
|
126,309
|
$
|
(48,574
|
)
|
$
|
181,401
|
|||||||||
Issuance of share capital (note 8)
|
3,490
|
‒
|
‒
|
‒
|
3,490
|
|||||||||||||||
Reclassification of stock-based compensation costs (note 8)
|
346
|
(346
|
)
|
‒
|
‒
|
‒
|
||||||||||||||
Stock-based compensation costs
|
‒
|
214
|
‒
|
‒
|
214
|
|||||||||||||||
Net earnings for the period
|
‒
|
‒
|
3,303
|
‒
|
3,303
|
|||||||||||||||
Other comprehensive loss
|
||||||||||||||||||||
Foreign currency translation adjustment
|
‒
|
‒
|
‒
|
(4,217
|
)
|
(4,217
|
)
|
|||||||||||||
Changes in unrealized gains/losses on forward exchange contracts, net of deferred income taxes of $92
|
‒
|
‒
|
‒
|
(288
|
)
|
(288
|
)
|
|||||||||||||
Total comprehensive loss for the period
|
(1,202
|
)
|
||||||||||||||||||
Balance as at November 30, 2016
|
$
|
89,352
|
$
|
18,018
|
$
|
129,612
|
$
|
(53,079
|
)
|
$
|
183,903
|
Three months ended November 30, 2017
|
||||||||||||||||||||
Share
capital
|
Contributed surplus
|
Retained earnings
|
Accumulated other comprehensive loss
|
Total
shareholders' equity
|
||||||||||||||||
Balance as at September 1, 2017
|
$
|
90,411
|
$
|
18,184
|
$
|
127,160
|
$
|
(38,965
|
)
|
$
|
196,790
|
|||||||||
Reclassification of stock-based compensation costs (note 8)
|
598
|
(598
|
)
|
‒
|
‒
|
‒
|
||||||||||||||
Stock-based compensation costs
|
‒
|
430
|
‒
|
‒
|
430
|
|||||||||||||||
Net earnings for the period
|
‒
|
‒
|
2,679
|
‒
|
2,679
|
|||||||||||||||
Other comprehensive loss
|
||||||||||||||||||||
Foreign currency translation adjustment
|
‒
|
‒
|
‒
|
(4,130
|
)
|
(4,130
|
)
|
|||||||||||||
Changes in unrealized gains/losses on forward exchange contracts, net of deferred income taxes of $215
|
‒
|
‒
|
‒
|
(692
|
)
|
(692
|
)
|
|||||||||||||
Total comprehensive loss for the period
|
(2,143
|
)
|
||||||||||||||||||
Balance as at November 30, 2017
|
$
|
91,009
|
$
|
18,016
|
$
|
129,839
|
$
|
(43,787
|
)
|
$
|
195,077
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Cash flows from operating activities
|
||||||||
Net earnings for the period
|
$
|
2,679
|
$
|
3,303
|
||||
Add (deduct) items not affecting cash
|
||||||||
Stock-based compensation costs
|
402
|
258
|
||||||
Depreciation and amortization
|
2,273
|
1,330
|
||||||
Write-off of capital assets
|
124
|
‒
|
||||||
Change in fair value of cash contingent consideration
|
(155
|
)
|
‒
|
|||||
Deferred revenue
|
(782
|
)
|
(75
|
)
|
||||
Deferred income taxes
|
(240
|
)
|
147
|
|||||
Changes in foreign exchange gain/loss
|
(247
|
)
|
(538
|
)
|
||||
4,054
|
4,425
|
|||||||
Changes in non-cash operating items
|
||||||||
Accounts receivable
|
1,085
|
(2,558
|
)
|
|||||
Income taxes and tax credits
|
59
|
(344
|
)
|
|||||
Inventories
|
(1,953
|
)
|
(1,248
|
)
|
||||
Prepaid expenses
|
318
|
258
|
||||||
Other assets
|
4
|
13
|
||||||
Accounts payable, accrued liabilities and provisions
|
(1,369
|
)
|
(1,425
|
)
|
||||
Other liabilities
|
188
|
‒
|
||||||
2,386
|
(879
|
)
|
||||||
Cash flows from investing activities
|
||||||||
Additions to short-term investments
|
(234
|
)
|
(296
|
)
|
||||
Purchases of capital assets
|
(1,991
|
)
|
(1,237
|
)
|
||||
Investment in an associate (note 3)
|
(10,311
|
)
|
‒
|
|||||
Business combination, net of cash acquired (note 3)
|
(9,540
|
)
|
(5,000
|
)
|
||||
(22,076
|
)
|
(6,533
|
)
|
|||||
Cash flows from financing activities
|
||||||||
Bank loan
|
2
|
‒
|
||||||
Repayment of long-term debt
|
(70
|
)
|
‒
|
|||||
(68
|
)
|
‒
|
||||||
Effect of foreign exchange rate changes on cash
|
(226
|
)
|
(735
|
)
|
||||
Change in cash
|
(19,984
|
)
|
(8,147
|
)
|
||||
Cash – Beginning of the period
|
38,435
|
43,208
|
||||||
Cash – End of the period
|
$
|
18,451
|
$
|
35,061
|
||||
Supplementary information
|
||||||||
Income taxes paid
|
$
|
682
|
$
|
958
|
1
|
Nature of Activities and Incorporation
|
2
|
Basis of Presentation
|
3
|
Investment in an Associate and Business Combination
|
Assets acquired
|
||||
Accounts receivable
|
$
|
1,889
|
||
Inventories
|
2,504
|
|||
Property, plant and equipment
|
1,424
|
|||
Intangible assets
|
3,374
|
|||
Other assets
|
171
|
|||
9,362
|
||||
Liabilities assumed
|
||||
Accounts payable and accrued liabilities
|
1,035
|
|||
Long-term debt (note 7)
|
2,143
|
|||
Deferred income taxes
|
1,160
|
|||
Net identifiable assets acquired
|
5,024
|
|||
Goodwill
|
4,516
|
|||
Fair value of the total consideration transferred, net of cash acquired
|
$
|
9,540
|
Balance – Beginning of the period
|
$
|
35,077
|
||
Business combination
|
4,516
|
|||
Foreign currency translation adjustment
|
(389
|
)
|
||
Balance – End of the period
|
$
|
39,204
|
4
|
Restructuring Charges
|
Balance – Beginning of the period
|
$
|
2,477
|
||
Payments
|
(1,085
|
)
|
||
Reversal
|
(356
|
)
|
||
Balance – End of the period
|
$
|
1,036
|
5
|
Financial Instruments
|
Level 1: |
Quoted prices (unadjusted) in active markets for identical assets or liabilities
|
Level 2: |
Inputs other than quoted prices included within Level 1 that are observable for the asset and liability, either directly or indirectly
|
Level 3: |
Unobservable inputs for the asset or liability
|
As at November 30, 2017
|
As at August 31, 2017
|
|||||||||||||||||||||||
Level 1
|
Level 2
|
Level 3
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||||||||
Financial assets
|
||||||||||||||||||||||||
Short-term investments
|
$
|
1,004
|
$
|
‒
|
$
|
‒
|
$
|
775
|
$
|
‒
|
$
|
‒
|
||||||||||||
Forward exchange contracts
|
$
|
‒
|
$
|
1,245
|
$
|
‒
|
$
|
‒
|
$
|
2,258
|
$
|
‒
|
||||||||||||
Financial liabilities
|
||||||||||||||||||||||||
Contingent liability
|
$
|
‒
|
$
|
‒
|
$
|
985
|
$
|
‒
|
$
|
‒
|
$
|
1,092
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual forward rates
|
|||||||
December 2017 to August 2018
|
$
|
16,100
|
1.3349
|
||||||
September 2018 to August 2019
|
11,100
|
1.3413
|
|||||||
Total
|
$
|
27,200
|
1.3375
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual forward rates
|
|||||||
December 2017 to August 2018
|
$
|
2,200
|
68.94
|
||||||
September 2018 to February 2019
|
4,000
|
67.72
|
|||||||
Total
|
$
|
6,200
|
68.15
|
6
|
Credit Facilities
|
7
|
Long-term Debt
|
As at
November 30,
2017
|
As at
August 31,
2017
|
|||||||
Unsecured, non-interest-bearing loan, denominated in euros, repayable in quarterly instalments of €17,250 (US$20,519) starting in June 2019, maturing in March 2024
|
$
|
380
|
$
|
‒
|
||||
Unsecured, non-interest-bearing loan, denominated in euros, repayable in quarterly instalments of €22,850 (US$27,180) starting in June 2020, maturing in March 2025
|
500
|
‒
|
||||||
Loans, secured by the universality of the assets of a subsidiary, denominated in euros, repayable in monthly instalments, bearing interest at annual rates of 0.7% to 2.0%, maturing at different dates between December 2017 to August 2022
|
1,125
|
‒
|
||||||
Other long-term debt
|
100
|
‒
|
||||||
2,105
|
‒
|
|||||||
Current portion of long-term debt
|
510
|
‒
|
||||||
$
|
1,595
|
$
|
‒
|
As at
November 30,
2017
|
As at
August 31,
2017
|
|||||||
No later than one year
|
$
|
510
|
$
|
‒
|
||||
Later than one year and no later than five years
|
1,300
|
‒
|
||||||
Later than five years
|
395
|
‒
|
||||||
$
|
2,205
|
$
|
‒
|
8
|
Share Capital
|
Three months ended November 30, 2016
|
||||||||||||||||||||
Multiple voting shares
|
Subordinate voting shares
|
|||||||||||||||||||
Number
|
Amount
|
Number
|
Amount
|
Total
amount
|
||||||||||||||||
Balance as at September 1, 2016
|
31,643,000
|
$
|
1
|
21,917,942
|
$
|
85,515
|
$
|
85,516
|
||||||||||||
Issuance of share capital
|
−
|
−
|
793,070
|
3,490
|
3,490
|
|||||||||||||||
Redemption of restricted share units
|
−
|
−
|
88,371
|
−
|
−
|
|||||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
346
|
346
|
|||||||||||||||
Balance as at November 30, 2016
|
31,643,000
|
$
|
1
|
22,799,383
|
$
|
89,351
|
$
|
89,352
|
Three months ended November 30, 2017
|
||||||||||||||||||||
Multiple voting shares
|
Subordinate voting shares
|
|||||||||||||||||||
Number
|
Amount
|
Number
|
Amount
|
Total
amount
|
||||||||||||||||
Balance as at September 1, 2017
|
31,643,000
|
$
|
1
|
23,068,777
|
$
|
90,410
|
$
|
90,411
|
||||||||||||
Redemption of restricted share units
|
−
|
−
|
155,619
|
−
|
−
|
|||||||||||||||
Reclassification of stock-based compensation costs to share capital upon exercise of stock awards
|
−
|
−
|
−
|
598
|
598
|
|||||||||||||||
Balance as at November 30, 2017
|
31,643,000
|
$
|
1
|
23,224,396
|
$
|
91,008
|
$
|
91,009
|
9
|
Statements of Earnings
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Gross research and development expenses
|
$
|
13,063
|
$
|
12,640
|
||||
Research and development tax credits and grants
|
(1,811
|
)
|
(1,326
|
)
|
||||
Net research and development expenses for the period
|
$
|
11,252
|
$
|
11,314
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Inventory write-down for the period
|
$
|
703
|
$
|
494
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Cost of sales
|
||||||||
Depreciation of property, plant and equipment
|
$
|
472
|
$
|
359
|
||||
Amortization of intangible assets
|
911
|
296
|
||||||
1,383
|
655
|
|||||||
Selling and administrative expenses
|
||||||||
Depreciation of property, plant and equipment
|
164
|
118
|
||||||
Amortization of intangible assets
|
112
|
19
|
||||||
276
|
137
|
|||||||
Net research and development expenses
|
||||||||
Depreciation of property, plant and equipment
|
518
|
426
|
||||||
Amortization of intangible assets
|
96
|
112
|
||||||
614
|
538
|
|||||||
$
|
2,273
|
$
|
1,330
|
|||||
Depreciation of property, plant and equipment
|
$
|
1,154
|
$
|
903
|
||||
Amortization of intangible assets
|
1,119
|
427
|
||||||
$
|
2,273
|
$
|
1,330
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Salaries and benefits
|
$
|
29,622
|
$
|
28,778
|
||||
Stock-based compensation costs
|
402
|
258
|
||||||
Total employee compensation for the period
|
$
|
30,024
|
$
|
29,036
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Cost of sales
|
$
|
36
|
$
|
27
|
||||
Selling and administrative expenses
|
276
|
179
|
||||||
Net research and development expenses
|
90
|
52
|
||||||
Total stock-based compensation for the period
|
$
|
402
|
$
|
258
|
10
|
Income Taxes
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Income tax provision at combined Canadian federal and provincial statutory tax rate (27%)
|
$
|
1,193
|
$
|
1,422
|
||||
Increase (decrease) due to:
|
||||||||
Foreign income taxed at different rates
|
(103
|
)
|
(172
|
)
|
||||
Non-deductible loss (non-taxable income)
|
(54
|
)
|
194
|
|||||
Non-deductible expenses
|
381
|
173
|
||||||
Change in tax rates
|
‒
|
(89
|
)
|
|||||
Foreign exchange effect of translation of foreign subsidiaries
|
(92
|
)
|
(122
|
)
|
||||
Utilization of previously unrecognized deferred income tax assets
|
(244
|
)
|
(156
|
)
|
||||
Unrecognized deferred income tax assets on temporary deductible differences and unused tax losses
|
1,035
|
850
|
||||||
Other
|
(376
|
)
|
(138
|
)
|
||||
Income tax provision for the period
|
$
|
1,740
|
$
|
1,962
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Current
|
$
|
1,980
|
$
|
1,815
|
||||
Deferred
|
(240
|
)
|
147
|
|||||
$
|
1,740
|
$
|
1,962
|
11
|
Earnings per Share
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Basic weighted average number of shares outstanding (000's)
|
54,805
|
53,884
|
||||||
Plus dilutive effect of (000's):
|
||||||||
Restricted share units
|
813
|
958
|
||||||
Deferred share units
|
175
|
159
|
||||||
Diluted weighted average number of shares outstanding (000's)
|
55,793
|
55,001
|
||||||
Stock awards excluded from the calculation of diluted weighted average number of shares outstanding because their exercise price was greater than the average market price of the common shares (000's)
|
124
|
−
|
Three months ended
November 30,
|
Three months ended
November 30,
|
|||||||||||||||
2017
|
2016
|
2017
|
2016
|
|||||||||||||
Sales
|
$
|
63,391
|
$
|
61,785
|
100.0
|
%
|
100.0
|
%
|
||||||||
Cost of sales (1)
|
23,289
|
22,813
|
36.7
|
36.9
|
||||||||||||
Selling and administrative
|
23,193
|
21,595
|
36.6
|
35.0
|
||||||||||||
Net research and development
|
11,252
|
11,314
|
17.8
|
18.3
|
||||||||||||
Depreciation of property, plant and equipment
|
1,154
|
903
|
1.8
|
1.4
|
||||||||||||
Amortization of intangible assets
|
1,119
|
427
|
1.8
|
0.7
|
||||||||||||
Change in fair value of cash contingent consideration
|
(155
|
)
|
‒
|
(0.2
|
)
|
‒
|
||||||||||
Interest and other (income) expense
|
338
|
(20
|
)
|
0.5
|
‒
|
|||||||||||
Foreign exchange gain
|
(1,218
|
)
|
(512
|
)
|
(1.9
|
)
|
(0.8
|
)
|
||||||||
Earnings before income taxes
|
4,419
|
5,265
|
6.9
|
8.5
|
||||||||||||
Income taxes
|
1,740
|
1,962
|
2.7
|
3.2
|
||||||||||||
Net earnings for the period
|
$
|
2,679
|
$
|
3,303
|
4.2
|
%
|
5.3
|
%
|
||||||||
Basic and diluted net earnings per share
|
$
|
0.05
|
$
|
0.06
|
||||||||||||
Other selected information:
|
||||||||||||||||
Gross margin before depreciation and amortization (2)
|
$
|
40,102
|
$
|
38,972
|
63.3
|
%
|
63.1
|
%
|
||||||||
Research and development:
|
||||||||||||||||
Gross research and development
|
$
|
13,063
|
$
|
12,640
|
20.6
|
%
|
20.5
|
%
|
||||||||
Net research and development
|
$
|
11,252
|
$
|
11,314
|
17.8
|
%
|
18.3
|
%
|
||||||||
Adjusted EBITDA (2)
|
$
|
6,059
|
$
|
6,321
|
9.6
|
%
|
10.2
|
%
|
(1)
|
Cost of sales is exclusive of depreciation and amortization, shown separately.
|
(2)
|
Refer to page 36 for non-IFRS measures.
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Physical-layer product line
|
$
|
42,513
|
$
|
42,016
|
||||
Protocol-layer product line
|
20,641
|
20,009
|
||||||
63,154
|
62,025
|
|||||||
Foreign exchange gains (losses) on forward exchange contracts
|
237
|
(240
|
)
|
|||||
Total sales
|
$
|
63,391
|
$
|
61,785
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Physical-layer product line
|
$
|
48,352
|
$
|
44,090
|
||||
Protocol-layer product line
|
17,290
|
22,009
|
||||||
65,642
|
66,099
|
|||||||
Foreign exchange gains (losses) on forward exchange contracts
|
237
|
(240
|
)
|
|||||
Total bookings
|
$
|
65,879
|
$
|
65,859
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
Americas
|
53
|
%
|
56
|
%
|
||||
EMEA
|
23
|
23
|
||||||
APAC
|
24
|
21
|
||||||
100
|
%
|
100
|
%
|
Acquisition of investment in Astellia
|
$
|
(10,311
|
)
|
|
Acquisition of Yenista
|
(9,540
|
)
|
||
Purchases of capital assets
|
(1,991
|
)
|
||
Unrealized foreign exchange loss on cash and short-term investments
|
(226
|
)
|
||
Cash flows provided by operating activities
|
2,386
|
|||
Other
|
(73
|
)
|
||
$
|
(19,755
|
)
|
Long-term
debt
|
Operating
leases
|
Licensing
agreements
|
Total
|
|||||||||||||
No later than one year
|
$
|
510
|
$
|
2,444
|
$
|
1,385
|
$
|
4,339
|
||||||||
Later than one year and no later than five years
|
1,300
|
7,243
|
1,410
|
9,953
|
||||||||||||
Later than five years
|
395
|
1,431
|
‒
|
1,826
|
||||||||||||
$
|
2,205
|
$
|
11,118
|
$
|
2,795
|
$
|
16,118
|
Expiry dates
|
Contractual
amounts
|
Weighted average
contractual
forward rates
|
||||||
December 2017 to August 2018
|
$
|
16,100,000
|
1.3349
|
|||||
September 2018 to August 2019
|
11,100,000
|
1.3413
|
||||||
Total
|
$
|
27,200,000
|
1.3375
|
Expiry dates
|
Contractual
amounts
|
Weighted average contractual
forward rates
|
||||||
December 2017 to August 2018
|
$
|
2,200,000
|
68.94
|
|||||
September 2018 to February 2019
|
4,000,000
|
67.72
|
||||||
$
|
6,200,000
|
68.15
|
Three months ended
November 30,
|
||||||||
2017
|
2016
|
|||||||
IFRS net earnings for the period
|
$
|
2,679
|
$
|
3,303
|
||||
Add (deduct):
|
||||||||
Depreciation
|
1,154
|
903
|
||||||
Amortization
|
1,119
|
427
|
||||||
Interest and other (income) expense
|
338
|
(20
|
)
|
|||||
Income taxes
|
1,740
|
1,962
|
||||||
Stock-based compensation costs
|
402
|
258
|
||||||
Change in fair value of cash contingent consideration
|
(155
|
)
|
–
|
|||||
Foreign exchange gain
|
(1,218
|
)
|
(512
|
)
|
||||
Adjusted EBITDA for the period
|
$
|
6,059
|
$
|
6,321
|
||||
Adjusted EBITDA in percentage of sales
|
9.6
|
%
|
10.2
|
%
|
Quarters ended
|
||||||||||||||||
November 30,
2017
|
August 31,
2017
|
May 31,
2017
|
February 28,
2017
|
|||||||||||||
Sales
|
$
|
63,391
|
$
|
62,981
|
$
|
58,505
|
$
|
60,030
|
||||||||
Cost of sales (2)
|
$
|
23,289
|
$
|
23,972
|
$
|
24,555
|
$
|
22,989
|
||||||||
Net earnings (loss)
|
$
|
2,679
|
$
|
844
|
$
|
(4,304
|
)
|
$
|
1,008
|
|||||||
Basic and diluted net earnings (loss) per share
|
$
|
0.05
|
$
|
0.02
|
$
|
(0.08
|
)
|
$
|
0.02
|
Quarters ended
|
||||||||||||||||
November 30,
2016
|
August 31,
2016
|
May 31,
2016
|
February 29,
2016
|
|||||||||||||
Sales
|
$
|
61,785
|
$
|
62,858
|
$
|
60,896
|
$
|
53,597
|
||||||||
Cost of sales (2)
|
$
|
22,813
|
$
|
24,145
|
$
|
23,880
|
$
|
18,904
|
||||||||
Net earnings
|
$
|
3,303
|
$
|
2,252
|
$
|
919
|
$
|
3,963
|
||||||||
Basic and diluted net earnings per share
|
$
|
0.06
|
$
|
0.04
|
$
|
0.02
|
$
|
0.07
|
(1)
|
Quarterly financial information has been derived from our condensed unaudited interim consolidated financial statements, which are prepared in accordance with the IFRS, as issued by the IASB, applicable to the preparation of interim financial statements, including IAS 34, "Interim Financial Reporting". The presentation currency is the US dollar, which differs from the functional currency of the company (Canadian dollar).
|
(2)
|
The cost of sales is exclusive of depreciation and amortization.
|
1. |
Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of EXFO Inc. (the "issuer") for the interim period ended November 30, 2017.
|
2. |
No misrepresentation: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
|
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
|
4. |
Responsibility: The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in Regulation 52-109 respecting Certification of Disclosure in Issuer's Annual and Interim Filings (c. V-1.1, r. 27), for the issuer.
|
5. |
Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer and I have, as at the end of the period covered by the interim filings
|
(a) |
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
(i) |
material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
|
(ii) |
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
|
(b) |
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.
|
5.1 |
Control framework: The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is the Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
|
5.2 |
N/A
|
5.3 |
N/A
|
6. |
Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on September 1, 2017 and ended on November 30, 2017 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.
|
1. |
Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of EXFO Inc. (the "issuer") for the interim period ended November 30, 2017.
|
2. |
No misrepresentation: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
|
3. |
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
|
4. |
Responsibility: The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in Regulation 52-109 respecting Certification of Disclosure in Issuer's Annual and Interim Filings (c. V-1.1, r. 27), for the issuer.
|
5. |
Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer and I have, as at the end of the period covered by the interim filings
|
(a) |
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
|
(i) |
material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
|
(ii) |
information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
|
(b) |
designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.
|
5.1 |
Control framework: The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is the Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
|
5.2 |
N/A
|
5.3 |
N/A
|
6. |
Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on September 1, 2017 and ended on November 30, 2017 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.
|